Impact of COVID-19 on Drug Development in Rare Disease and Oncology
The full effect of the COVID-19 pandemic, particularly on the search for rare disease and oncology treatments, is still uncertain. What we do know is that patients diagnosed with these conditions simply cannot afford delays. With a patient-centric approach and guided by the best minds in the industry, Parexel has a broad perspective to help sponsors, regulators, and patients during this difficult time. We have learned a great deal over the past few months about trial conduct, patient recruitment, risk mitigation, the pace of regulatory approvals, and how patients are faring. And now we want to share this information with you.
Related Insights
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers
Mar 31, 2026
Playbook
Preparing clinical infrastructure for radiopharmaceutical trials
Mar 11, 2026
Blog
Do we still need broad patient representation in breast cancer trials? Absolutely.
Oct 17, 2025
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Audiogram
New FDA regulatory initiatives improving rare disease drug development
Sep 23, 2025
Whitepaper
Early and often: reimagining patient community engagement to improve clinical trials feasibility
Feb 27, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Related Insights
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
FDA novel oncology drug approvals in 2025: Trends and strategic insights for developers
Mar 31, 2026
Playbook
Preparing clinical infrastructure for radiopharmaceutical trials
Mar 11, 2026
Blog
Do we still need broad patient representation in breast cancer trials? Absolutely.
Oct 17, 2025
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Audiogram
New FDA regulatory initiatives improving rare disease drug development
Sep 23, 2025
Whitepaper
Early and often: reimagining patient community engagement to improve clinical trials feasibility
Feb 27, 2025
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025